CARDIOPROGRESS
Foundation for the advancement of cardiology

Guideline on the Management of Dyslipidemia The new 2026 ACC/AHA/AACVPR et al. Guidelines for the Management of Dyslipidemia have been published. These guidelines address the assessment, treatment, and monitoring of individuals with dyslipidemia, including high blood cholesterol, elevated triglycerides, and elevated lipoprotein(a) [Lp(a)]. These new guidelines address primary, secondary, and primary prevention, provide guidance for care of adults and children, reinstate risk-based treatment targets for low-density lipoprotein (LDL) cholesterol, and replace the 2018 AHA/ACC/Multisociety Cholesterol Treatment Guidelines.

Quadpill Strategy Gains Ground in Hypertension Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension. Agents such as baxdrostat, the first selective aldosterone synthase inhibitor, and aprocitentan, a dual endothelin receptor A and B antagonist, are paving the way for new drug combinations and a more personalized approach to blood pressure control.

The New Playbook for Ditching Dangerous Senior Meds A new tool presented at the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting may give clinicians practical and safer alternatives to risky medications for patients.

International Research in Cardiology 2010-2014 Dear colleagues!
The Cardioprogress Foundation presents the book «International Research in Cardiology», which includes the results of the most important international clinical trials presented in 2010-2024. The authors systematized studies in 21 sections, which include risk factors, antiplatelet and anticoagulant therapy, laboratory and instrumental diagnostics, arrhythmia, invasive cardiology, valvular heart diseases, intensive care in cardiology and more.

New Drug Combos Could Cut Heart Failure Mortality by 60% Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference.

Dedicated to eternal memory Dear colleagues!
On these holidays, the Cardioprogress Foundation remembers the heroes of the Great Patriotic War, whose feat was immortalized in the hearts of their descendants.

Spanish Cardiologists Release Gender-Specific CV Guide The Spanish Society of Cardiology (SEC) Working Group on Women and Cardiovascular Diseases (SEC-GT CVD in Women) and the Association of Preventive Cardiology have convened an interdisciplinary group of experts from various Spanish societies and associations issued SEC-approved clinical guidelines published in the English-language edition of the Revista Española de Cardiología journal, which is designed to help medical professionals. in the diagnosis and treatment of cardiovascular diseases in women, paying special attention to gender differences.

Risk Model Validates Finerenone Effect in Heart Failure The Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction (PREDICT-HFpEF) tool effectively stratified cardiovascular risk, with risk being higher in the highest than in the lowest score quintile. Finerenone was consistently effective across risk levels in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), with a large absolute benefit observed in high-risk patients.

Muslim fasting from a medical point of view Dear colleagues!
We offer you an article by Professor Mekhman N. Mamedov about medical aspects of muslim fasting and practical advice for applicants.

Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. Bill is developing a new therapeutic approach targeting CXCR3 for the treatment of myocarditis with immunotherapy.